Comparative Pharmacology
Head-to-head clinical analysis: ADLYXIN versus LIRAGLUTIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADLYXIN versus LIRAGLUTIDE.
ADLYXIN vs LIRAGLUTIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Subcutaneous injection: 10 mcg once daily within 60 minutes before the first meal of the day; may increase to 20 mcg once daily after 2 weeks.
Liraglutide is administered subcutaneously once daily. For type 2 diabetes, start at 0.6 mg daily for one week, then increase to 1.2 mg daily; may further increase to 1.8 mg daily if needed. For weight management (with BMI ≥30 or ≥27 with comorbidities), start at 0.6 mg daily for one week, then escalate weekly by 0.6 mg to a target dose of 3.0 mg daily.
None Documented
None Documented
Terminal elimination half-life is 2–3 hours after subcutaneous administration, supporting a twice-daily dosing regimen.
The terminal elimination half-life of liraglutide after subcutaneous administration is approximately 13 hours, supporting once-daily dosing. The prolonged half-life is due to albumin binding and reduced renal clearance.
Renal (predominantly via glomerular filtration and proteolytic degradation; approximately 35% of the dose is excreted unchanged in urine, with the remainder as metabolites and small peptides).
Liraglutide is primarily eliminated via degradation into smaller peptides and amino acids, with no significant renal or biliary excretion of the intact drug. Approximately 6% of the dose is excreted unchanged in urine, and less than 5% is excreted in feces as intact liraglutide.
Category C
Category C
GLP-1 Receptor Agonist
GLP-1 Receptor Agonist